Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1644 1646 1674 1678 1783
This examiner grants 57% of resolved cases
Ashley Hartman Gao serves in Tech Center 1700 and Art Unit 1644. She has handled 90 resolved cases, resulting in an allowance rate of 56.7 percent. This 56.7 percent allowance rate indicates the frequency of applications reaching a final disposition under her review that are granted. With 90 resolved cases, the data provides a clear baseline for her examination style.
The interview lift for Gao is 38.2 percent. This 38.2 percent lift is very high, suggesting that interviews are an extremely effective strategy for increasing the likelihood of allowance compared to cases without an interview. The 38.2 percent lift indicates that cases with an interview are significantly more likely to be granted than those without. Practitioners should prioritize scheduling interviews to address rejections and advance prosecution in Art Unit 1644.
The median time to allowance is 1238 days. This 1238 day duration represents the typical timeframe from filing to patent issuance. Applicants should factor this 1238 day median into their long-term planning and expectations for pendency. The combination of the 56.7 percent allowance rate and this median provides a comprehensive view of the prosecution environment for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16961026 | Fusion Protein Extensions | Final Rejection | NantBio, Inc. |
| 18104825 | T CELL-BASED METHODS FOR PREDICTING POLYPEPTIDE IMMUNOGENICITY | Non-Final OA | GENENTECH, INC. |
| 17168621 | USE OF TRYPTOPHAN DERIVATIVES AND L-METHIONINE FOR PROTEIN FORMULATION | Final Rejection | Genentech, Inc. |
| 18245868 | IDENTIFICATION OF SARS-COV-2 EPITOPES DISCRIMINATING COVID-19 INFECTION FROM CONTROL AND METHODS OF USE | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 18027292 | Devices and Methods for Evaluating the Viability of Embryos | Final Rejection | The Regents of the University of California |
| 17776131 | SYSTEMS AND METHODS FOR RAPID, SENSITIVE MULTIPLEX IMMUNOASSAYS | Final Rejection | The Regents of the University of Michigan |
| 17905580 | SUBCUTANEOUS ABSORPTION AND BIOAVAILABILITY OF ANTIBODIES | Final Rejection | Eli Lilly and Company |
| 18265661 | FEATURES FOR DETERMINING DUCTAL CARCINOMA IN SITU RECURRENCE AND PROGRESSION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18560223 | CONTROL SLIDE GLASS FOR PATHOLOGICAL EXAMINATION AND METHOD FOR MANUFACTURING SAME | Final Rejection | Hitachi High-Tech Corporation |
| 17924748 | DETECTION METHOD OF TARGET MOLECULE IN SPECIMEN AND DETECTION KIT FOR TARGET MOLECULE | Final Rejection | Yokogawa Electric Corporation |
| 18283434 | METHODS OF DETERMINING POTENCY OF A THERAPEUTIC CELL COMPOSITION | Non-Final OA | Juno Therapeutics, Inc. |
| 17641473 | ASSAY FOR IMMUNE CELL RECOVERY | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 16980128 | IMMUNO-EXOSOMES AND METHODS OF USE THEREOF | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18180991 | SYSTEMS AND METHODS FOR PREDICTING GRAFT DYSFUNCTION WITH EXOSOME PROTEINS | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18808311 | BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17199195 | CSF-1R ANTIBODY FORMULATION | Final Rejection | Hoffmann-La Roche Inc. |
| 18435746 | TIGIT AND CD112R BLOCKADE | Non-Final OA | AMGEN INC. |
| 17289970 | METHOD FOR PRODUCING PLURIPOTENT STEM CELL HAVING RELEASED DIFFERENTIATION RESISTANCE TO MESENDODERM | Final Rejection | Kyoto University |
| 18065736 | MEASURING FREQUENCY OF PATHOGEN-SPECIFIC T CELLS IN PERIPHERAL BLOOD | Final Rejection | Thomas Jefferson University |
| 18625703 | NOVEL PD-1 BINDING DOMAINS | Non-Final OA | INCYTE CORPORATION |
| 18625756 | NOVEL PD-1 BINDING DOMAINS | Non-Final OA | INCYTE CORPORATION |
| 17819810 | TUMOR SUPPRESSION BY MODULATION OF NON-CANONICAL AUTOPHAGY (LAP) IN MYELOID CELLS | Final Rejection | St. Jude Children's Research Hospital |
| 17128599 | BISPECIFIC SIGNALING AGENTS AND USES THEREOF | Non-Final OA | Universiteit Gent |
| 17274564 | METHODS FOR DECREASING INFLUENZA-INDUCED LETHALITY USING GASTRIN-RELEASING PEPTIDE (GRP) INHIBITORS OR GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) ANTAGONISTS | Final Rejection | The United States of America, as represented by the Secretary, Department of Health and Human Servic |
| 18369273 | BIOLOGICAL CONJUGATES HAVING AN PHOTOGENERATED ACIDIC OR BASIC RELEASABLE DETECTION MOIETY ON TOP OF BIOLOGICAL TISSUES | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18024603 | CONJUGATES HAVING AN ENZYMMATICALLY RELEASABLE DETECTION MOIETY AND A BARCODE MOIETY | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy